Editas Medicine, Inc. (EDIT) 10-Year Financial Performance & Capital Metrics

EDIT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Show more

Revenue $32M -58.6%
EBITDA -$245M -50.4%
Net Income -$237M -54.7%
EPS (Diluted) -2.88 -42.6%
Gross Margin 100% +8.4%
EBITDA Margin -759.25% -263.6%
Operating Margin -777.22% -258.9%
Net Margin -733.72% -274.1%
ROE -98.1% -127.2%
ROIC -120.84% -155.8%
Debt/Equity 0.26 +87.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y9.5%

3Y8.15%

TTM-24.9%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM5.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.03%

ROCE

10Y Avg-42.85%

5Y Avg-42.63%

3Y Avg-50.47%

Latest-71.73%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.63M	6.05M	13.73M	31.94M	20.53M	90.73M	25.54M	19.71M	78.12M	32.31M
Revenue Growth %	-	2.72%	1.27%	1.33%	-0.36%	3.42%	-0.72%	-0.23%	2.96%	-0.59%
Cost of Goods Sold+	18.85M	56.98M	83.16M	90.65M	96.9M	158M	5.05M	6.34M	6.06M	0
COGS % of Revenue	11.57%	9.41%	6.06%	2.84%	4.72%	1.74%	0.2%	0.32%	0.08%	-
Gross Profit+	-17.22M	-50.93M	-69.43M	-58.72M	-76.37M	-67.26M	20.49M	13.38M	72.06M	32.31M
Gross Margin %	-10.57%	-8.41%	-5.06%	-1.84%	-3.72%	-0.74%	0.8%	0.68%	0.92%	1%
Gross Profit Growth %	-2.39%	-1.96%	-0.36%	0.15%	-0.3%	0.12%	1.3%	-0.35%	4.39%	-0.55%
Operating Expenses+	36.94M	103.24M	133.66M	145.66M	64.56M	67.58M	213.64M	239.32M	241.24M	283.47M
OpEx % of Revenue	22.68%	17.06%	9.74%	4.56%	3.14%	0.74%	8.36%	12.14%	3.09%	8.77%
Selling, General & Admin	18.09M	46.26M	50.5M	55.01M	64.56M	67.58M	76.18M	70.7M	69.65M	71.99M
SG&A % of Revenue	11.11%	7.64%	3.68%	1.72%	3.14%	0.74%	2.98%	3.59%	0.89%	2.23%
Research & Development	18.85M	56.98M	83.16M	90.65M	96.9M	158M	142.51M	174.96M	177.65M	199.25M
R&D % of Revenue	11.57%	9.41%	6.06%	2.84%	4.72%	1.74%	5.58%	8.88%	2.27%	6.17%
Other Operating Expenses	-37.45M	-57K	587K	328K	-96.9M	-158M	-5.05M	-6.34M	-6.06M	12.23M
Operating Income+	-35.31M	-97.19M	-119.93M	-113.73M	-140.92M	-134.84M	-193.15M	-225.95M	-169.18M	-251.15M
Operating Margin %	-21.68%	-16.06%	-8.74%	-3.56%	-6.86%	-1.49%	-7.56%	-11.46%	-2.17%	-7.77%
Operating Income Growth %	-1.78%	-1.75%	-0.23%	0.05%	-0.24%	0.04%	-0.43%	-0.17%	0.25%	-0.48%
EBITDA+	-34.84M	-95.99M	-117.25M	-110.47M	-138.09M	-130.88M	-188.09M	-219.61M	-163.12M	-245.34M
EBITDA Margin %	-21.39%	-15.86%	-8.54%	-3.46%	-6.73%	-1.44%	-7.36%	-11.14%	-2.09%	-7.59%
EBITDA Growth %	-1.77%	-1.75%	-0.22%	0.06%	-0.25%	0.05%	-0.44%	-0.17%	0.26%	-0.5%
D&A (Non-Cash Add-back)	471K	1.2M	2.68M	3.25M	2.83M	3.96M	5.05M	6.34M	6.06M	5.81M
EBIT	-72.76M	-97.25M	-119.35M	-113.73M	-140.92M	-134.84M	-193.15M	-225.95M	-169.18M	-238.92M
Net Interest Income+	-143K	62K	-978K	3.44M	7.31M	2.6M	607K	5.52M	17.57M	14.06M
Interest Income	0	62K	0	3.44M	7.31M	2.6M	607K	5.52M	17.57M	14.06M
Interest Expense	143K	0	978K	0	0	0	0	0	0	0
Other Income/Expense	-37.59M	5K	-391K	3.77M	7.18M	18.86M	644K	5.52M	15.96M	14.06M
Pretax Income+	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Pretax Margin %	-44.75%	-16.06%	-8.76%	-3.44%	-6.51%	-1.28%	-7.54%	-11.18%	-1.96%	-7.34%
Income Tax+	0	0	-1.12M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Net Margin %	-44.75%	-16.06%	-8.76%	-3.44%	-6.51%	-1.28%	-7.54%	-11.18%	-1.96%	-7.34%
Net Income Growth %	-4.33%	-0.33%	-0.24%	0.09%	-0.22%	0.13%	-0.66%	-0.15%	0.3%	-0.55%
Net Income (Continuing)	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.04	-3.02	-2.98	-2.33	-2.47	-1.98	-2.85	-3.21	-2.02	-2.88
EPS Growth %	0.62%	-0.48%	0.01%	0.22%	-0.06%	0.2%	-0.44%	-0.13%	0.37%	-0.43%
EPS (Basic)	-2.04	-3.02	-2.98	-2.33	-2.47	-1.98	-2.85	-3.21	-2.02	-2.88
Diluted Shares Outstanding	35.7M	32.22M	40.32M	47.1M	49.98M	58.61M	67.62M	68.66M	75.97M	82.34M
Basic Shares Outstanding	35.7M	32.22M	40.32M	47.1M	49.98M	58.61M	67.62M	68.66M	75.97M	82.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	144.99M	187.18M	332.2M	374.78M	463.84M	419.09M	507.31M	356.75M	340.83M	289.31M
Cash & Short-Term Investments	143.18M	185.32M	329.14M	368.95M	457.14M	402.11M	499.85M	344.27M	323.11M	269.91M
Cash Only	143.18M	185.32M	146.63M	134.78M	238.18M	139.68M	203.52M	141.52M	123.65M	131.54M
Short-Term Investments	0	0	182.51M	234.18M	218.96M	262.43M	296.33M	202.75M	199.46M	138.37M
Accounts Receivable	1.02M	88K	679K	30K	418K	6.05M	267K	5.14M	10.19M	16.27M
Days Sales Outstanding	228.32	5.31	18.05	0.34	7.43	24.33	3.82	95.27	47.59	183.73
Inventory	780K	1.66M	1.86M	2.92M	0	0	0	0	0	0
Days Inventory Outstanding	15.11	10.65	8.18	11.75	-	-	-	-	-	-
Other Current Assets	326K	110K	517K	0	6.29M	0	0	7.33M	7.53M	3.14M
Total Non-Current Assets+	4.38M	42M	41.06M	45.61M	45.04M	153.51M	170.17M	157.57M	158.32M	52.27M
Property, Plant & Equipment	2.13M	40.38M	39.44M	40.23M	39.65M	39.15M	43.29M	59.22M	45.71M	47.05M
Fixed Asset Turnover	0.76x	0.15x	0.35x	0.79x	0.52x	2.32x	0.59x	0.33x	1.71x	0.69x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	1.62M	1.62M	5.38M	3.67M	109.66M	120.07M	93.1M	104.02M	0
Other Non-Current Assets	2.25M	0	0	0	1.73M	4.7M	6.81M	5.25M	8.59M	5.22M
Total Assets+	149.36M	229.18M	373.26M	420.39M	508.88M	572.6M	677.48M	514.32M	499.15M	341.59M
Asset Turnover	0.01x	0.03x	0.04x	0.08x	0.04x	0.16x	0.04x	0.04x	0.16x	0.09x
Asset Growth %	11.25%	0.53%	0.63%	0.13%	0.21%	0.13%	0.18%	-0.24%	-0.03%	-0.32%
Total Current Liabilities+	6.92M	33.08M	36.71M	35.9M	59.96M	58.21M	46.88M	60.11M	63.22M	77.22M
Accounts Payable	1.38M	4.64M	4.02M	5.33M	5.84M	6.41M	5.05M	9.51M	8.27M	5.49M
Days Payables Outstanding	26.75	29.72	17.64	21.45	22.01	14.8	364.78	547.82	497.72	-
Short-Term Debt	0	10M	7.5M	0	0	0	0	0	12M	0
Deferred Revenue (Current)	88K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.06M	1M	8.24M	9.66M	19.83M	5.32M	10.16M	10.14M	-723K	21.99M
Current Ratio	20.94x	5.66x	9.05x	10.44x	7.74x	7.20x	10.82x	5.94x	5.39x	3.75x
Quick Ratio	20.82x	5.61x	9.00x	10.36x	7.74x	7.20x	10.82x	5.94x	5.39x	3.75x
Cash Conversion Cycle	216.68	-13.77	8.59	-9.36	-	-	-	-	-	-
Total Non-Current Liabilities+	225.55M	61.49M	128.47M	148.32M	186.49M	120.81M	76.96M	93.53M	86.84M	130.09M
Long-Term Debt	199.91M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	35.1M	33.43M	32.42M	23.28M	19.32M	16.07M	32.86M	24.37M	20.38M
Deferred Tax Liabilities	289K	380K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	316K	396K	317K	293K	1K	27.5M	0	0	1.8M	3.07M
Total Liabilities	232.48M	94.58M	165.18M	184.22M	246.45M	179.02M	123.84M	153.64M	150.06M	207.31M
Total Debt+	199.91M	35.1M	33.43M	32.42M	29.08M	26.14M	26.38M	43.95M	48.54M	35.03M
Net Debt	56.73M	-150.23M	-113.2M	-102.36M	-209.1M	-113.55M	-177.14M	-97.58M	-75.11M	-96.51M
Debt / Equity	-	0.26x	0.16x	0.14x	0.11x	0.07x	0.05x	0.12x	0.14x	0.26x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-246.94x	-	-122.63x	-	-	-	-	-	-	-
Total Equity+	-83.11M	134.61M	208.08M	236.16M	262.44M	393.59M	553.64M	360.68M	349.1M	134.27M
Equity Growth %	-4.44%	2.62%	0.55%	0.13%	0.11%	0.5%	0.41%	-0.35%	-0.03%	-0.62%
Book Value per Share	-2.33	4.18	5.16	5.01	5.25	6.72	8.19	5.25	4.60	1.63
Total Shareholders' Equity	-83.11M	134.61M	208.08M	236.16M	262.44M	393.59M	553.64M	360.68M	349.1M	134.27M
Common Stock	0	4K	4K	5K	5K	6K	7K	7K	8K	8K
Retained Earnings	-88.35M	-185.53M	-305.85M	-416.28M	-549.22M	-665.2M	-857.7M	-1.08B	-1.23B	-1.47B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-229.18M	-76K	-29K	107K	-46K	-493K	-3.6M	198K	268K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.4M	-49.93M	-9.42M	-45.71M	-40.67M	-179.84M	-163.8M	-177.35M	-132.18M	-210.28M
Operating CF Margin %	-3.32%	-8.25%	-0.69%	-1.43%	-1.98%	-1.98%	-6.41%	-9%	-1.69%	-6.51%
Operating CF Growth %	0.38%	-8.24%	0.81%	-3.85%	0.11%	-3.42%	0.09%	-0.08%	0.25%	-0.59%
Net Income	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Depreciation & Amortization	471K	1.2M	2.68M	3.25M	2.83M	3.96M	5.05M	6.34M	6.06M	5.81M
Stock-Based Compensation	3.51M	16.88M	23.36M	26.6M	27.24M	23.16M	43.4M	29.29M	19.8M	21.42M
Deferred Taxes	84K	87K	0	-3.67M	0	-16.37M	0	0	0	0
Other Non-Cash Items	306K	10.56M	14.2M	11.17M	-2.93M	27.6M	1.66M	-724K	-3.23M	-3.87M
Working Capital Changes	63.12M	18.53M	70.66M	26.89M	65.93M	-102.22M	-21.41M	8.18M	-1.59M	3.45M
Change in Receivables	-1.02M	931K	-591K	649K	-388K	-5.63M	5.78M	-4.88M	-5.04M	-6.08M
Change in Inventory	4.8M	13.1M	-8.94M	1.57M	10.65M	-5.65M	-3.35M	0	0	0
Change in Payables	-1.44M	3.25M	-1.51M	1.78M	274K	855K	-1.14M	4.37M	-1.49M	-2.29M
Cash from Investing+	-1.43M	-5.09M	-183.81M	-53.09M	12.25M	-140.52M	-54.47M	114.07M	-3.73M	162.15M
Capital Expenditures	-1.43M	-3.49M	-2.06M	-4.75M	-6.17M	-7.16M	-7.98M	-4.12M	-4.72M	-8.83M
CapEx % of Revenue	0.88%	0.58%	0.15%	0.15%	0.3%	0.08%	0.31%	0.21%	0.06%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-241K	-1.6M	15K	37K	0	0	-46.49M	0	0	0
Cash from Financing+	139.39M	97.16M	154.53M	86.94M	131.82M	224.12M	282.11M	1.28M	118.04M	56.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	139.89M	233K	155.3M	11.01M	15.48M	20.4M	32.65M	0	960K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.83M	-53.42M	-11.48M	-50.46M	-46.84M	-187M	-171.78M	-181.47M	-136.9M	-219.11M
FCF Margin %	-4.2%	-8.83%	-0.84%	-1.58%	-2.28%	-2.06%	-6.72%	-9.21%	-1.75%	-6.78%
FCF Growth %	0.31%	-6.82%	0.79%	-3.4%	0.07%	-2.99%	0.08%	-0.06%	0.25%	-0.6%
FCF per Share	-0.19	-1.66	-0.28	-1.07	-0.94	-3.19	-2.54	-2.64	-1.80	-2.66
FCF Conversion (FCF/Net Income)	0.07x	0.51x	0.08x	0.42x	0.30x	1.55x	0.85x	0.80x	0.86x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-377.46%	-70.22%	-49.5%	-53.65%	-35.36%	-40.65%	-48.22%	-43.17%	-98.1%
Return on Invested Capital (ROIC)	-	-	-226.97%	-74.6%	-112.96%	-60.67%	-44.13%	-52.99%	-47.25%	-120.84%
Gross Margin	-1056.91%	-841.33%	-505.76%	-183.85%	-371.96%	-74.13%	80.22%	67.85%	92.24%	100%
Net Margin	-4475.14%	-1605.53%	-876.49%	-344.28%	-651.43%	-127.82%	-753.61%	-1118.26%	-196.13%	-733.72%
Debt / Equity	-	0.26x	0.16x	0.14x	0.11x	0.07x	0.05x	0.12x	0.14x	0.26x
Interest Coverage	-246.94x	-	-122.63x	-	-	-	-	-	-	-
FCF Conversion	0.07x	0.51x	0.08x	0.42x	0.30x	1.55x	0.85x	0.80x	0.86x	0.89x
Revenue Growth	-	271.58%	126.8%	132.64%	-35.71%	341.93%	-71.85%	-22.83%	296.32%	-58.64%

Revenue by Segment

	2024
Reportable	32.31M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Editas Medicine, Inc. (EDIT) reported $46.4M in revenue for fiscal year 2024.

Editas Medicine, Inc. (EDIT) saw revenue decline by 58.6% over the past year.

Editas Medicine, Inc. (EDIT) reported a net loss of $199.8M for fiscal year 2024.

Dividend & Returns

Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -98.1%. Negative ROE indicates the company is unprofitable.

Editas Medicine, Inc. (EDIT) had negative free cash flow of $180.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Editas Medicine, Inc. (EDIT) 10-Year Financial Performance & Capital Metrics

EDIT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $32M -58.6%
EBITDA -$245M -50.4%
Net Income -$237M -54.7%
EPS (Diluted) -2.88 -42.6%
Gross Margin 100% +8.4%
EBITDA Margin -759.25% -263.6%
Operating Margin -777.22% -258.9%
Net Margin -733.72% -274.1%
ROE -98.1% -127.2%
ROIC -120.84% -155.8%
Debt/Equity 0.26 +87.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y9.5%

3Y8.15%

TTM-24.9%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM5.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.03%

ROCE

10Y Avg-42.85%

5Y Avg-42.63%

3Y Avg-50.47%

Latest-71.73%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.63M	6.05M	13.73M	31.94M	20.53M	90.73M	25.54M	19.71M	78.12M	32.31M
Revenue Growth %	-	2.72%	1.27%	1.33%	-0.36%	3.42%	-0.72%	-0.23%	2.96%	-0.59%
Cost of Goods Sold+	18.85M	56.98M	83.16M	90.65M	96.9M	158M	5.05M	6.34M	6.06M	0
COGS % of Revenue	11.57%	9.41%	6.06%	2.84%	4.72%	1.74%	0.2%	0.32%	0.08%	-
Gross Profit+	-17.22M	-50.93M	-69.43M	-58.72M	-76.37M	-67.26M	20.49M	13.38M	72.06M	32.31M
Gross Margin %	-10.57%	-8.41%	-5.06%	-1.84%	-3.72%	-0.74%	0.8%	0.68%	0.92%	1%
Gross Profit Growth %	-2.39%	-1.96%	-0.36%	0.15%	-0.3%	0.12%	1.3%	-0.35%	4.39%	-0.55%
Operating Expenses+	36.94M	103.24M	133.66M	145.66M	64.56M	67.58M	213.64M	239.32M	241.24M	283.47M
OpEx % of Revenue	22.68%	17.06%	9.74%	4.56%	3.14%	0.74%	8.36%	12.14%	3.09%	8.77%
Selling, General & Admin	18.09M	46.26M	50.5M	55.01M	64.56M	67.58M	76.18M	70.7M	69.65M	71.99M
SG&A % of Revenue	11.11%	7.64%	3.68%	1.72%	3.14%	0.74%	2.98%	3.59%	0.89%	2.23%
Research & Development	18.85M	56.98M	83.16M	90.65M	96.9M	158M	142.51M	174.96M	177.65M	199.25M
R&D % of Revenue	11.57%	9.41%	6.06%	2.84%	4.72%	1.74%	5.58%	8.88%	2.27%	6.17%
Other Operating Expenses	-37.45M	-57K	587K	328K	-96.9M	-158M	-5.05M	-6.34M	-6.06M	12.23M
Operating Income+	-35.31M	-97.19M	-119.93M	-113.73M	-140.92M	-134.84M	-193.15M	-225.95M	-169.18M	-251.15M
Operating Margin %	-21.68%	-16.06%	-8.74%	-3.56%	-6.86%	-1.49%	-7.56%	-11.46%	-2.17%	-7.77%
Operating Income Growth %	-1.78%	-1.75%	-0.23%	0.05%	-0.24%	0.04%	-0.43%	-0.17%	0.25%	-0.48%
EBITDA+	-34.84M	-95.99M	-117.25M	-110.47M	-138.09M	-130.88M	-188.09M	-219.61M	-163.12M	-245.34M
EBITDA Margin %	-21.39%	-15.86%	-8.54%	-3.46%	-6.73%	-1.44%	-7.36%	-11.14%	-2.09%	-7.59%
EBITDA Growth %	-1.77%	-1.75%	-0.22%	0.06%	-0.25%	0.05%	-0.44%	-0.17%	0.26%	-0.5%
D&A (Non-Cash Add-back)	471K	1.2M	2.68M	3.25M	2.83M	3.96M	5.05M	6.34M	6.06M	5.81M
EBIT	-72.76M	-97.25M	-119.35M	-113.73M	-140.92M	-134.84M	-193.15M	-225.95M	-169.18M	-238.92M
Net Interest Income+	-143K	62K	-978K	3.44M	7.31M	2.6M	607K	5.52M	17.57M	14.06M
Interest Income	0	62K	0	3.44M	7.31M	2.6M	607K	5.52M	17.57M	14.06M
Interest Expense	143K	0	978K	0	0	0	0	0	0	0
Other Income/Expense	-37.59M	5K	-391K	3.77M	7.18M	18.86M	644K	5.52M	15.96M	14.06M
Pretax Income+	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Pretax Margin %	-44.75%	-16.06%	-8.76%	-3.44%	-6.51%	-1.28%	-7.54%	-11.18%	-1.96%	-7.34%
Income Tax+	0	0	-1.12M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Net Margin %	-44.75%	-16.06%	-8.76%	-3.44%	-6.51%	-1.28%	-7.54%	-11.18%	-1.96%	-7.34%
Net Income Growth %	-4.33%	-0.33%	-0.24%	0.09%	-0.22%	0.13%	-0.66%	-0.15%	0.3%	-0.55%
Net Income (Continuing)	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.04	-3.02	-2.98	-2.33	-2.47	-1.98	-2.85	-3.21	-2.02	-2.88
EPS Growth %	0.62%	-0.48%	0.01%	0.22%	-0.06%	0.2%	-0.44%	-0.13%	0.37%	-0.43%
EPS (Basic)	-2.04	-3.02	-2.98	-2.33	-2.47	-1.98	-2.85	-3.21	-2.02	-2.88
Diluted Shares Outstanding	35.7M	32.22M	40.32M	47.1M	49.98M	58.61M	67.62M	68.66M	75.97M	82.34M
Basic Shares Outstanding	35.7M	32.22M	40.32M	47.1M	49.98M	58.61M	67.62M	68.66M	75.97M	82.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	144.99M	187.18M	332.2M	374.78M	463.84M	419.09M	507.31M	356.75M	340.83M	289.31M
Cash & Short-Term Investments	143.18M	185.32M	329.14M	368.95M	457.14M	402.11M	499.85M	344.27M	323.11M	269.91M
Cash Only	143.18M	185.32M	146.63M	134.78M	238.18M	139.68M	203.52M	141.52M	123.65M	131.54M
Short-Term Investments	0	0	182.51M	234.18M	218.96M	262.43M	296.33M	202.75M	199.46M	138.37M
Accounts Receivable	1.02M	88K	679K	30K	418K	6.05M	267K	5.14M	10.19M	16.27M
Days Sales Outstanding	228.32	5.31	18.05	0.34	7.43	24.33	3.82	95.27	47.59	183.73
Inventory	780K	1.66M	1.86M	2.92M	0	0	0	0	0	0
Days Inventory Outstanding	15.11	10.65	8.18	11.75	-	-	-	-	-	-
Other Current Assets	326K	110K	517K	0	6.29M	0	0	7.33M	7.53M	3.14M
Total Non-Current Assets+	4.38M	42M	41.06M	45.61M	45.04M	153.51M	170.17M	157.57M	158.32M	52.27M
Property, Plant & Equipment	2.13M	40.38M	39.44M	40.23M	39.65M	39.15M	43.29M	59.22M	45.71M	47.05M
Fixed Asset Turnover	0.76x	0.15x	0.35x	0.79x	0.52x	2.32x	0.59x	0.33x	1.71x	0.69x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	1.62M	1.62M	5.38M	3.67M	109.66M	120.07M	93.1M	104.02M	0
Other Non-Current Assets	2.25M	0	0	0	1.73M	4.7M	6.81M	5.25M	8.59M	5.22M
Total Assets+	149.36M	229.18M	373.26M	420.39M	508.88M	572.6M	677.48M	514.32M	499.15M	341.59M
Asset Turnover	0.01x	0.03x	0.04x	0.08x	0.04x	0.16x	0.04x	0.04x	0.16x	0.09x
Asset Growth %	11.25%	0.53%	0.63%	0.13%	0.21%	0.13%	0.18%	-0.24%	-0.03%	-0.32%
Total Current Liabilities+	6.92M	33.08M	36.71M	35.9M	59.96M	58.21M	46.88M	60.11M	63.22M	77.22M
Accounts Payable	1.38M	4.64M	4.02M	5.33M	5.84M	6.41M	5.05M	9.51M	8.27M	5.49M
Days Payables Outstanding	26.75	29.72	17.64	21.45	22.01	14.8	364.78	547.82	497.72	-
Short-Term Debt	0	10M	7.5M	0	0	0	0	0	12M	0
Deferred Revenue (Current)	88K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.06M	1M	8.24M	9.66M	19.83M	5.32M	10.16M	10.14M	-723K	21.99M
Current Ratio	20.94x	5.66x	9.05x	10.44x	7.74x	7.20x	10.82x	5.94x	5.39x	3.75x
Quick Ratio	20.82x	5.61x	9.00x	10.36x	7.74x	7.20x	10.82x	5.94x	5.39x	3.75x
Cash Conversion Cycle	216.68	-13.77	8.59	-9.36	-	-	-	-	-	-
Total Non-Current Liabilities+	225.55M	61.49M	128.47M	148.32M	186.49M	120.81M	76.96M	93.53M	86.84M	130.09M
Long-Term Debt	199.91M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	35.1M	33.43M	32.42M	23.28M	19.32M	16.07M	32.86M	24.37M	20.38M
Deferred Tax Liabilities	289K	380K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	316K	396K	317K	293K	1K	27.5M	0	0	1.8M	3.07M
Total Liabilities	232.48M	94.58M	165.18M	184.22M	246.45M	179.02M	123.84M	153.64M	150.06M	207.31M
Total Debt+	199.91M	35.1M	33.43M	32.42M	29.08M	26.14M	26.38M	43.95M	48.54M	35.03M
Net Debt	56.73M	-150.23M	-113.2M	-102.36M	-209.1M	-113.55M	-177.14M	-97.58M	-75.11M	-96.51M
Debt / Equity	-	0.26x	0.16x	0.14x	0.11x	0.07x	0.05x	0.12x	0.14x	0.26x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-246.94x	-	-122.63x	-	-	-	-	-	-	-
Total Equity+	-83.11M	134.61M	208.08M	236.16M	262.44M	393.59M	553.64M	360.68M	349.1M	134.27M
Equity Growth %	-4.44%	2.62%	0.55%	0.13%	0.11%	0.5%	0.41%	-0.35%	-0.03%	-0.62%
Book Value per Share	-2.33	4.18	5.16	5.01	5.25	6.72	8.19	5.25	4.60	1.63
Total Shareholders' Equity	-83.11M	134.61M	208.08M	236.16M	262.44M	393.59M	553.64M	360.68M	349.1M	134.27M
Common Stock	0	4K	4K	5K	5K	6K	7K	7K	8K	8K
Retained Earnings	-88.35M	-185.53M	-305.85M	-416.28M	-549.22M	-665.2M	-857.7M	-1.08B	-1.23B	-1.47B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-229.18M	-76K	-29K	107K	-46K	-493K	-3.6M	198K	268K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.4M	-49.93M	-9.42M	-45.71M	-40.67M	-179.84M	-163.8M	-177.35M	-132.18M	-210.28M
Operating CF Margin %	-3.32%	-8.25%	-0.69%	-1.43%	-1.98%	-1.98%	-6.41%	-9%	-1.69%	-6.51%
Operating CF Growth %	0.38%	-8.24%	0.81%	-3.85%	0.11%	-3.42%	0.09%	-0.08%	0.25%	-0.59%
Net Income	-72.9M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-192.5M	-220.43M	-153.22M	-237.09M
Depreciation & Amortization	471K	1.2M	2.68M	3.25M	2.83M	3.96M	5.05M	6.34M	6.06M	5.81M
Stock-Based Compensation	3.51M	16.88M	23.36M	26.6M	27.24M	23.16M	43.4M	29.29M	19.8M	21.42M
Deferred Taxes	84K	87K	0	-3.67M	0	-16.37M	0	0	0	0
Other Non-Cash Items	306K	10.56M	14.2M	11.17M	-2.93M	27.6M	1.66M	-724K	-3.23M	-3.87M
Working Capital Changes	63.12M	18.53M	70.66M	26.89M	65.93M	-102.22M	-21.41M	8.18M	-1.59M	3.45M
Change in Receivables	-1.02M	931K	-591K	649K	-388K	-5.63M	5.78M	-4.88M	-5.04M	-6.08M
Change in Inventory	4.8M	13.1M	-8.94M	1.57M	10.65M	-5.65M	-3.35M	0	0	0
Change in Payables	-1.44M	3.25M	-1.51M	1.78M	274K	855K	-1.14M	4.37M	-1.49M	-2.29M
Cash from Investing+	-1.43M	-5.09M	-183.81M	-53.09M	12.25M	-140.52M	-54.47M	114.07M	-3.73M	162.15M
Capital Expenditures	-1.43M	-3.49M	-2.06M	-4.75M	-6.17M	-7.16M	-7.98M	-4.12M	-4.72M	-8.83M
CapEx % of Revenue	0.88%	0.58%	0.15%	0.15%	0.3%	0.08%	0.31%	0.21%	0.06%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-241K	-1.6M	15K	37K	0	0	-46.49M	0	0	0
Cash from Financing+	139.39M	97.16M	154.53M	86.94M	131.82M	224.12M	282.11M	1.28M	118.04M	56.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	139.89M	233K	155.3M	11.01M	15.48M	20.4M	32.65M	0	960K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.83M	-53.42M	-11.48M	-50.46M	-46.84M	-187M	-171.78M	-181.47M	-136.9M	-219.11M
FCF Margin %	-4.2%	-8.83%	-0.84%	-1.58%	-2.28%	-2.06%	-6.72%	-9.21%	-1.75%	-6.78%
FCF Growth %	0.31%	-6.82%	0.79%	-3.4%	0.07%	-2.99%	0.08%	-0.06%	0.25%	-0.6%
FCF per Share	-0.19	-1.66	-0.28	-1.07	-0.94	-3.19	-2.54	-2.64	-1.80	-2.66
FCF Conversion (FCF/Net Income)	0.07x	0.51x	0.08x	0.42x	0.30x	1.55x	0.85x	0.80x	0.86x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-377.46%	-70.22%	-49.5%	-53.65%	-35.36%	-40.65%	-48.22%	-43.17%	-98.1%
Return on Invested Capital (ROIC)	-	-	-226.97%	-74.6%	-112.96%	-60.67%	-44.13%	-52.99%	-47.25%	-120.84%
Gross Margin	-1056.91%	-841.33%	-505.76%	-183.85%	-371.96%	-74.13%	80.22%	67.85%	92.24%	100%
Net Margin	-4475.14%	-1605.53%	-876.49%	-344.28%	-651.43%	-127.82%	-753.61%	-1118.26%	-196.13%	-733.72%
Debt / Equity	-	0.26x	0.16x	0.14x	0.11x	0.07x	0.05x	0.12x	0.14x	0.26x
Interest Coverage	-246.94x	-	-122.63x	-	-	-	-	-	-	-
FCF Conversion	0.07x	0.51x	0.08x	0.42x	0.30x	1.55x	0.85x	0.80x	0.86x	0.89x
Revenue Growth	-	271.58%	126.8%	132.64%	-35.71%	341.93%	-71.85%	-22.83%	296.32%	-58.64%

Revenue by Segment

	2024
Reportable	32.31M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Editas Medicine, Inc. (EDIT) reported $46.4M in revenue for fiscal year 2024.

Editas Medicine, Inc. (EDIT) saw revenue decline by 58.6% over the past year.

Editas Medicine, Inc. (EDIT) reported a net loss of $199.8M for fiscal year 2024.

Dividend & Returns

Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -98.1%. Negative ROE indicates the company is unprofitable.

Editas Medicine, Inc. (EDIT) had negative free cash flow of $180.7M in fiscal year 2024, likely due to heavy capital investments.